A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
Not yet recruiting · NCT07622342 · Registry updated 2026-06-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Not yet recruiting | Phase 2 | 2026-06-03 | NCT07622342 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Guangdong Hengrui Pharmaceutical Co., Ltd | 31 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Huashan Hospital, Fudan University | Shanghai | China | 40 |
| Xiangya Hospital of Central South University | Changsha | China | 47 |